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ACE457 is a recently identiﬁed pancreatic isoform of
human 
 
 
 
-secretase. We report that this membrane
glycoprotein and its soluble variant are characterized by
inefﬁcient folding in the ER, leading to proteasome-mediated
ER-associated degradation (ERAD). Dissection of the
 
degradation process revealed that upon release from cal-
nexin, extensively oxidized BACE457 transiently entered in
disulﬁde-bonded complexes associated with the lumenal
chaperones BiP and protein disulﬁde isomerase (PDI)
before unfolding and dislocation into the cytosol for
degradation. BACE457 and its lumenal variant accumulated
in disulﬁde-bonded complexes, in the ER lumen, also
B
 
when protein degradation was inhibited. The complexes
were disassembled and the misfolded polypeptides were
cleared from the ER upon reactivation of the degradation
machinery. Our data offer new insights into the mechanism
of ERAD by showing a sequential involvement of the calnexin
and BiP/PDI chaperone systems. We report the unexpected
transient formation of covalent complexes in the ER lumen
during the ERAD process, and we show that PDI partici-
pates as an oxidoreductase and a redox-driven chaperone
in the preparation of proteins for degradation from the
mammalian ER.
 
Introduction
 
The quality control operating in the ER allows export of
only correctly folded and completely assembled polypep-
tides. Terminally misfolded proteins are transported into the
cytosol and degraded in processes collectively defined as ER-
associated degradation (ERAD)* (McCracken and Brodsky,
1996; Kopito, 1997; Ellgaard et al., 1999). The importance
of unraveling the mechanism(s) of ERAD in mammalian
cells is emphasized by the recent description of the decisive
role played by ERAD in hereditary human conformational
diseases, such as cystic fibrosis and 
 
 
 
1-antitrypsin deficiency
(Plemper and Wolf, 1999; Kopito and Ron, 2000). More-
over, pathogens exploit the host ERAD machinery to escape
immunosurveillance, as in the case of cytomegalovirus or
Epstein-Barr virus (Wiertz et al., 1996a; Levitskaya et al.,
1997), or to invade the host cytosol, as shown for bacterial
and plant toxins (Hazes and Read, 1997; Tsai et al., 2001).
Models depicting the ERAD mechanism(s) rely on inves-
tigation in yeast and mammalian cells of not more than a
dozen model glycoproteins and of few nonglycosylated pro-
teins (for reviews see Cabral et al., 2001; Fewell et al., 2001).
The picture emerging from these studies is that degradation
of aberrant ER products is mainly performed by the cytosolic
proteasome (Kopito and Sitia, 2000 and references therein).
The topological distinction between site of production and
site of degradation of ERAD substrates implies the export of
misfolded proteins through the translocon complex (disloca-
tion) (Wiertz et al., 1996b; Pilon et al., 1997; Plemper et al.,
1997). There is accumulating evidence that proteasomes are
strategically placed as a sentinel on the cytosolic face of
dislocons and that normally dislocation and degradation are
coupled events (Mayer et al., 1998; Mancini et al., 2000).
In mammalian cells, besides the overwhelming number of
studies on calnexin, whose role remains nevertheless contro-
versial (for review see Parodi, 2000), and the role of BiP in
the retention of misfolded or orphan polypeptides in the ER
lumen (Knittler et al., 1995), little is known about the in-
volvement of lumenal molecular chaperones and enzymes in
the ERAD process. In particular, although it has been
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shown that protein disulfide isomerase (PDI) is involved in
the ERAD process in yeast (Gillece et al., 1999) and in
protein dislocation in isolated microsomes (Tsai et al.,
2001), and that ERAD is regulated by redox potential
(Stafford and Bonifacino, 1991; Young et al., 1993; Cou-
rageot et al., 1999; Wilson et al., 2000), a direct implica-
tion of lumenal oxidoreductases in mammalian ERAD has
not been shown yet.
The type I membrane glycoprotein BACE457 is a re-
cently identified pancreatic isoform of human 
 
 
 
-secretase.
Compared with the brain isoform (BACE501), BACE457
is short of a 44–amino acid region located between the two
catalytic aspartyl residues. In contrast to BACE501, when
BACE457 is expressed in cells, it is retained in the ER in an
immature state (Bodendorf et al., 2001; Tanahashi and Ta-
bira, 2001). BACE501 cleaves the amyloid precursor pro-
tein to initiate the processing pathway leading to the gener-
ation of the 
 
 
 
-amyloid peptides deposited in the senile
plaques associated with Alzheimer’s disease (Selkoe, 2001).
BACE457 does not contribute significantly to amyloid pre-
cursor protein processing and its physiologic relevance re-
mains to be established.
In this report, we show that folding of BACE457 and of
its soluble variant, BACE457
 
 
 
, is inefficient. Most of the
protein transiently expressed in human cells is retained in
and degraded from the ER. Detailed analysis revealed that
BACE457 and BACE457
 
 
 
 entered first the ER folding ma-
chinery, namely the calnexin cycle, to explore conformations
characterized by the variable extent of intramolecular disul-
fide bonding. After release from calnexin, the terminally
misfolded polypeptides did associate with the lumenal chap-
erones BiP and PDI before dislocation into the cytosol and
proteasome-mediated degradation. Importantly, after release
from calnexin, most BACE457 entered into intermolecular
disulfide-bonded complexes that had to be disassembled in
the ER lumen to allow dislocation. Temporary inhibition of
the ERAD machinery revealed disulfide-bonded complexes
for the soluble variant BACE457
 
 
 
 as well. We show that in
the mammalian ER, the calnexin and the BiP/PDI chaper-
one systems work sequentially during the preparation of
ERAD substrates for dislocation and degradation. We report
that disulfide-bonded complexes may be formed in the ER
lumen as transient intermediates during the ERAD process
and that PDI acts as an oxidoreductase and as a redox-driven
molecular chaperone during protein degradation from the
mammalian ER.
 
Results
 
BACE457 and BACE457
 
 
 
 are ERAD substrates
 
BACE457 or the soluble variant BACE457
 
 
 
 were expressed
in transiently transfected human embryonic kidney (HEK)
293 cells. To determine the fate of these proteins, cells were
metabolically labeled, chased for various times, and cell ex-
tracts were analyzed after immunoprecipitation with BACE-
specific antibody by reducing SDS-PAGE. BACE was the
major labeled protein visible in the gels (Fig. 1, a and d, Red).
Figure 1. BACE457 and BACE457  are ERAD substrates. (a) Degradation of BACE457 during the chase is shown in the reducing gel. Kinetics 
of degradation were determined by densitometric analysis of the labeled protein. The lag phase of 90 min preceding the onset of BACE457 
degradation is shown at the top of the graph. (b) To determine the effect of various ERAD inhibitors on degradation of BACE457, cells were 
mock treated (30 or 420 min) or incubated with MG (20  M), Kif (1–10  g/ml), DJ (1 mM), N (5 mM), or MA (10 mM) during starvation, 
pulse, and a 420-min chase. Refer to Fig. 3 for analysis of the inhibitory effects by SDS-PAGE. (c) BACE457 or BACE501 were transiently 
expressed in HEK293 cells. EndoH sensitivity of the proteins was assessed 30 and 180 min after their synthesis. Most of BACE501 was 
transported to the Golgi compartment, where it became resistant to EndoH treatment (Res). BACE457 was efficiently retained in the ER and 
remained sensitive to the endoglycosidase (Sens) (d and e), as in a and b for BACE457 . 
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After a lag phase of 
 
 
 
90 min, the amount of labeled
BACE457 decreased with a half-life of 4 h (Fig. 1 a). As a con-
sequence, after 420 min of chase, 
 
 
 
90% of the labeled protein
had been degraded (Fig. 1, a and b). Treatment with ERAD
inhibitors, such as the proteasome inhibitors MG132 (MG)
and clasto-lactacystin 
 
 
 
-lactone (L) or the mannosidase I
inhibitor kifunensine (Kif; Liu et al., 1999), prevented
BACE457 degradation (Fig. 1 b and Fig. 3). Treatment with
inhibitors of lysosomal degradation or of autophagocytosis
(ammonium chloride [N] and 3-methyladenine [MA], respec-
tively; Fig. 1 b) did not protect BACE457 from degradation.
BACE457
 
 
 
 was degraded faster (
 
t
 
1/2
 
 
 
 
 
 40 min). The lag
phase for the soluble variant of BACE457 was only 15 min
(Fig. 1 d). Again, the 90% degradation observed after 75
min of chase in control cells (Fig. 1, d and e) was signifi-
cantly delayed by MG or Kif (Fig. 1 e and Fig. 3) or L (not
depicted) but not by the lysosomal or autophagocytosis in-
hibitors (Fig. 1 e). BACE457 and BACE457
 
 
 
 were retained
in the ER before being degraded. This was shown by the
preservation of EndoH sensitivity (Fig. 1 c), colocalization
with ER markers by immunofluorescence, lack of processing
of the propeptide, and absence of protein at the cell surface
or in the conditioned medium (unpublished data; Boden-
dorf et al., 2001; Tanahashi and Tabira, 2001). The brain
splicing variant, BACE501, expressed at similar levels in
transiently transfected HEK293 cells (Fig. 1 c), showed a
very efficient folding, was transported along the secretory
pathway, as shown by acquisition of EndoH resistance (Fig.
1 c), and was properly targeted at the plasma membrane
(Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999).
We concluded that the deletion of 44 residues in the
ectodomain of the pancreatic variant of BACE457 impaired
folding and rendered most of the protein expressed in hu-
man cells an ERAD substrate, as defined by the requirement
of mannose trimming and the involvement of the cytosolic
proteasome for degradation.
 
BACE457 and BACE457
 
 
 
 are extensively oxidized 
before the onset of degradation
 
To analyze the behavior of BACE457 and BACE457
 
 
 
 be-
fore and during degradation, samples were also analyzed by
nonreducing SDS-PAGE. Initially, the labeled proteins were
distributed in multiple bands that differed in the extent of
intrachain disulfide bonding and had therefore distinct elec-
trophoretic mobility (R, Ox1, and Ox2; BACE457, Fig. 2 a;
BACE457
 
 
 
, Fig. 2 d). The labeled species indicated with R
had the same mobility as BACE run under reducing condi-
tions (Fig.
 
 
 
2, a and d, Red), indicating that most of its cys-
teines were still not disulfide bonded. Two additional oxida-
tion intermediates of BACE (Ox1 and Ox2) were resolved
in nonreducing gels. Ox2 appeared later, had the fastest mo-
bility, and was the only form of BACE that was diamide re-
sistant (BACE457, Fig. 2 b). This showed that all cysteines
of Ox2 were in intramolecular disulfides and/or protected
from further oxidation.
BACE457 monomers (R
 
 
 
Ox1
 
 
 
Ox2) persisted for
 
 
 
30 min and then disappeared with a half-life of 
 
 
 
90 min
(Fig. 2 a and Fig. 2 c, Monomers). Monomers disappeared
therefore during the lag phase before the onset of degra-
dation (Fig. 1 a and Fig. 2 c). The disappearance of
BACE457 monomers correlated with the formation of dis-
ulfide-bonded complexes of heterogeneous size, visible as a
broad band of labeled material at the top of the nonreduc-
ing gels (Fig. 2 a, C). Full-length BACE457 was the major
labeled component of the complexes, as shown upon their
disassembly in reducing gels (Fig. 1 a). The formation of
disulfide-bonded complexes was a clear symptom of pro-
tein misfolding. Complexes accumulated during the lag
phase and disappeared with the same kinetics observed for
BACE457 degradation (Fig. 2 a and Fig. 2 c, Complexes).
We concluded that BACE457 and BACE457
 
 
 
 were ex-
tensively oxidized during a lag phase preceding protea-
some-mediated degradation. Intriguingly, degradation of
Figure 2. BACE457 and BACE457  are extensively 
oxidized before onset of degradation. (a) Samples 
were also analyzed by nonreducing SDS-PAGE to 
assess the oxidation state of BACE457 during the 
experiment. The oxidation intermediates of 
BACE457 (R, Ox1, and Ox2) and the disulfide-
bonded complexes (C) are indicated; upon reduction, 
BACE457 migrated as a single band (reducing 
lane, Red). (b) Cells expressing BACE457 were 
metabolically labeled and chased for 30 min. The 
chase was concluded with a 5-min incubation 
with ( ) or without ( ) 5 mM ice-cold diamide 
(diazenedicarboxylic acid bis[N,N-dimethylamide]), 
a cell permeable oxidant that induces aggregation 
of folding intermediates or misfolded proteins 
containing free SH groups (Tortorella et al., 1998). 
Aggregation of BACE475 upon treatment with 
diamide was determined by nonreducing SDS-
PAGE. (c) Quantification of BACE457 monomers 
(R Ox1 Ox2, dotted line, circles) and BACE457 
complexes (broken line, diamonds) was performed 
from nonreducing gels as described in the Materials 
and methods. (d) As in panel a for the soluble 
variant BACE457 . 
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BACE457 seemed to occur from a pool of disulfide-
bonded protein.
 
BACE remains degradation competent upon formation 
of disulfide-bonded complexes
 
We next investigated the fate of BACE457 and BACE457
 
 
 
when the ERAD machinery had been inhibited. Detergent
extracts of cells mock treated or treated with ERAD inhibi-
tors were immunoprecipitated and subjected to nonreducing
or reducing SDS-PAGE (Fig. 3, a and d).
ERAD inhibitors did not prevent the conversion of
BACE457 monomers in disulfide-bonded complexes, but
efficiently blocked the disappearance of the complexes (Fig.
3 a, Nonreducing, MG, L, and Kif) and the degradation of
the protein (Fig. 3 a, Reducing, MG, L, and Kif). Impor-
tantly, when the ERAD machinery was reactivated, e.g.,
upon washout of MG after the formation of disulfide-
bonded complexes, the protein contained in the complexes
was efficiently cleared from the cells (Fig. 3 b).
These data showed that aggregation of BACE457 was a
reversible process and that, for BACE457, disulfide-bonded
complexes represented a pool from which the protein was
degraded.
The soluble form, BACE457
 
 
 
, was retained in the mono-
meric, fully oxidized Ox2 status when degradation was in-
hibited with Kif (Fig. 3 d). When the proteasome was inhib-
ited, BACE457
 
 
 
 accumulated in the oxidized monomers
Ox1 and Ox2 as well as in disulfide-bonded complexes (Fig.
3 d, MG). As shown for BACE457, also the misfolded
BACE457
 
 
 
 contained in the complexes was efficiently
cleared from the cells when degradation was resumed upon
washout of the inhibitors (Fig. 3 e).
The oxidation states of BACE457 and BACE457
 
 
 
showed that they were not dislocated into the reducing cyto-
sol when degradation was blocked. Consistently, only
 
 
 
10% of the labeled proteins was isolated from the cytoso-
lic fraction obtained by ultracentrifugation of cell homoge-
nates (unpublished data). This is in keeping with emerging
evidence showing that dislocation and degradation are cou-
pled events both in yeast and mammalian cells (Mayer et al.,
1998; Mancini et al., 2000).
 
Accumulation of misfolded BACE457 in the ER causes 
an increase in the number, and not in the size, of 
disulfide-bonded complexes
 
To better characterize the disulfide-bonded complexes tran-
siently formed during BACE457 degradation, their size was
determined after a 30-min chase, when very little BACE457
was disulfide bonded, and after a 3-h chase, when approxi-
mately three times more protein was disulfide bonded (Fig.
2 c, Complexes). Cell extracts were prepared as described
above and sedimented through 10–25% sucrose gradients.
Fractions were collected, lighter first, precipitated with
BACE-specific antibody, and analyzed by SDS-PAGE. The
disulfide-bonded complexes were heterogeneous in size,
ranging from 120 to 800 kD, as determined by cosedimen-
tation of calibration markers (Fig. 3 c). Surprisingly, com-
plexes formed when the aggregation process had just begun
(i.e., after a 30-min chase) sedimented in the same fractions
as complexes isolated from cells in which most of the labeled
BACE was disulfide bonded (Fig. 3 c, 3-h chase). We con-
cluded that the accumulation of misfolded BACE457 in the
ER resulted in the formation of more complexes of the same
size rather than in the enlargement of preexisting complexes.
Taken together, the data presented in Figs. 1–3 showed that
complexes were units with a limited capacity for accepting
misfolded BACE457 and in which BACE457 remained deg-
radation competent.
Figure 3. ERAD substrates accumulate in disulfide-
bonded complexes and remain in a degradation-
competent state upon inhibition of the ERAD 
machinery. (a) About 90% of labeled BACE457 
was degraded in control cells after a 420-min 
chase (compare labeled BACE after 30 min and 
420 min, Reducing, ctrl). Incubation with DJ 
reproducibly accelerated BACE457 degradation, 
whereas MG, Kif, and L significantly prevented 
degradation (Reducing). Most of the protein 
remained in disulfide-bonded complexes upon 
inhibition of the ERAD machinery (Nonreducing). 
The slightly slower mobility of BACE457 observed 
when the Kif sample was run under reducing 
conditions confirmed that mannose trimming had 
been efficiently inhibited. (b) Cells were incubated 
for 1.5 h in the presence of the reversible proteasome 
inhibitor MG to induce accumulation of misfolded, 
disulfide-bonded BACE457 (0 min). Upon MG 
washout, the chase was continued for the times 
indicated. (c) To determine the size of the 
disulfide-bonded complexes, cells expressing 
BACE457 were pulsed with radioactivity and chased 
for 30 min (squares) or 3 h (diamonds). Cell 
extracts were sedimented through 10–25% sucrose 
gradients with calibration markers. Fractions were 
collected, lighter first, precipitated with BACE457-specific antibody, and subjected to nonreducing SDS-PAGE to determine the sedimentation 
coefficient of monomers and disulfide-bonded complexes. In the figure, only the position in the gradient of the complexes is shown. (d) As in 
panel a for BACE457 . (e) As in panel b for BACE457 . 
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Involvement of ER resident chaperones 
in the ERAD of BACE
 
To establish which ER resident protein associated with
BACE457 and BACE457
 
 
 
, cell extracts were immunopre-
cipitated with antibody to calnexin and calreticulin, lectin-
like molecular chaperones assisting the folding of glycopro-
teins (Trombetta and Helenius, 1998), to BiP, which assists
protein folding but also retains misfolded proteins in the
ER (Gething, 1999), and to several ER resident oxi-
doreductases (PDI, ERp57, ERp72, and ERp29; Ferrari
and Soling, 1999), which may regulate the reduction of in-
ter- and intrachain disulfide bonds to allow dislocation of
BACE457 or BACE457
 
 
 
 for degradation. After the first
immunoprecipitation with chaperone-specific antibody, the
samples were reimmunoprecipitated with an antibody to a
linear epitope of BACE. As discussed in detail below, of the
chaperones tested, only calnexin (Fig. 4, a and b), BiP (Fig.
4, c and d), and PDI (Fig. 5) associated with a detectable
amount of BACE.
 
Calnexin associates with monomeric BACE during the 
lag phase preceding the onset of degradation
 
Calnexin associated transiently only with the fully oxidized
Ox2 form of BACE457 and BACE457
 
 
 
 (Fig. 4, a and b).
The half-life of calnexin–BACE457 complexes was 
 
 
 
90
min (Fig. 4 e). It was significantly shorter for calnexin–
BACE457
 
 
 
 complexes (
 
 
 
20 min; Fig. 4 g). Both proteins
were associated with calnexin during the lag phase before
 
degradation. They were not degraded directly after release
from calnexin because kinetics of association with the chap-
erone (Fig. 4, e and g) was clearly distinct from kinetics of
BACE degradation (Fig. 1 a and d). Degradation was inhib-
ited when the glucosidase inhibitor 
 
N
 
-butyl-deoxynojirimy-
cin (DJ) was used to delay BACE457 and BACE457
 
 
 
 re-
lease from calnexin (see Materials and methods), showing
that both proteins were shielded from the degradation ma-
chinery when associated with the chaperone (unpublished
data). On the other hand, when DJ was used to prevent ac-
cess of BACE to the calnexin cycle (Fig. 4 f, gel), the half-life
of both proteins was reduced (Fig. 1, b and e, DJ; Fig. 3, a
and d, DJ; Fig. 4 f, DJ; Fig. 6 a, DJ). This was a conse-
quence of a significantly shorter lag phase. For example,
upon incubation with DJ, the lag phase before the onset of
BACE457 degradation was only 30 min (90 min in mock-
treated cells) and the protein half-life was 
 
 
 
3 h (4 h in
mock-treated cells) (Fig. 4 f).
The data showed a temporal correlation between release
of BACE457 monomers from calnexin (Fig. 4 e) and con-
version of the monomers into disulfide-bonded complexes
(Fig. 2 c) before degradation. Altogether, association with
calnexin was not required for targeting membrane-bound
and soluble BACE457 to the ERAD machinery. When as-
sociation with calnexin was prevented, degradation started
earlier. It was the time of association with calnexin that
determined the length of the lag phase during which
BACE457 and BACE457
 
 
 
 were protected from premature
aggregation and degradation.
Figure 4. Association of BACE457 and BACE457  with calnexin and BiP. (a) Cell extracts were immunoprecipitated with antibody to calnexin. 
After extensive washings, proteins were denatured and the BACE457 associated with the chaperone was extracted with an antibody to a 
linear BACE epitope. Samples were then subjected to SDS-PAGE. (b) The same for BACE457 . (c and d) As in panels a and b, but with 
antibody to BiP. (e) Kinetics of BACE457 association with calnexin, BiP, and PDI was determined from reducing gels. Kinetics was 
indistinguishable for BiP and PDI. Association of PDI with BACE is shown in Fig. 5. (f) Kinetics of BACE457 degradation was determined in cells 
treated during starvation, pulse, and chase with 1 mM DJ to prevent BACE association with calnexin (DJ) or in mock-treated cells (Control). DJ 
efficiently prevented BACE457 association with calnexin. (g) Kinetics of BACE457  association with calnexin, BiP, and PDI, as in panel e. 
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BiP and PDI associate with misfolded and 
disulfide-bonded BACE
 
BiP (Fig. 4, c and d) and PDI (Fig. 5) associated transiently
with both variants of BACE457. The half-life of BACE457
complexes with BiP and with PDI was 4 h (Fig. 4 e); the half-
life of complexes containing BACE457
 
 
 
 was 40 min (Fig. 4
g). Kinetics of BACE457 and BACE457
 
 
 
 association with
BiP and PDI were indistinguishable from kinetics of BACE
degradation, showing that release from the BiP/PDI chaper-
one system and degradation were tightly coupled events.
BiP associated at first with the partially oxidized forms of the
newly synthesized ERAD candidates (Fig. 4, c and d, R and
Ox1, 0-min chase). Later on, and throughout their presence in
the ER lumen, BiP was associated with disulfide-bonded com-
plexes generated upon release of misfolded BACE457 from cal-
nexin (Fig. 4 c) or with misfolded BACE457
 
 
 
 in different oxi-
dation states (Fig. 4 d). The association of BiP with the early
folding intermediates R and Ox1 and that of calnexin with the
more oxidized species Ox2 showed a sequential involvement of
these two chaperones during the folding attempts before degra-
dation, as shown previously for a number of newly synthesized
proteins (Molinari and Helenius, 2000). Normally, proteins
complete their folding in the calnexin cycle, and then are trans-
ported along the secretory pathway. This was observed, for ex-
ample, for BACE501 under the same experimental conditions
(Fig. 1 c). For BACE457 and BACE457
 
 
 
, however, folding at-
tempts failed and upon release from calnexin, the misfolded
products did associate with BiP and PDI to be eventually de-
graded. These data show for the first time that the glycoprotein-
specific calnexin cycle and the BiP/PDI chaperone system may
act sequentially not only to assist protein folding but also to
warrant ERAD of misfolded products.
 
Analysis of PDI association with BACE by 
diagonal gel electrophoresis
 
PDI was the only lumenal oxidoreductase (among those
tested, see above) found to associate transiently with
 
BACE457. The involvement of PDI in the ERAD of both
BACE457 variants was analyzed in detail with a powerful
two-dimensional (2-D) SDS-PAGE technique (Fig. 5) previ-
ously used to establish the involvement of oxidoreductases in
protein oxidation during folding in vivo (diagonal gel elec-
trophoresis; Molinari and Helenius, 1999, 2002). Cell ex-
tracts were prepared before the onset of BACE degradation
(after a 10-min chase), or when degradation was in progress
(after a 180-min chase for BACE457 and after a 75-min
chase for BACE457
 
 
 
, respectively; Fig. 5). After immuno-
precipitation with antibodies to BACE or PDI and stringent
washing, labeled proteins were separated in diagonal gels.
The reduced form of BACE (R) is devoid of disulfide
bonds. It had therefore the same mobility under nonreduc-
ing and reducing conditions and was on the diagonal of the
gels. Ox1 and Ox2 were below the diagonal, as expected for
proteins with intramolecular disulfide bonds (Fig. 5, Anti-
BACE and AntiPDI). Radioactivity was also visible above
the diagonal of the gels, showing that labeled proteins were
involved in intermolecular disulfide-bonded complexes (Fig.
5, a–f). Complexes were more abundant for BACE457, as al-
ready shown in Fig. 2, and were distributed along a vertical
line in two distinct regions above the diagonal of the gels (ar-
rows C and MD), showing that they were heterogeneous in
size (as shown in Fig. 3 c) and variable in disulfide bonding.
Complexes labeled with C had an estimated molecular mass
above 200 kD; those labeled as MD were of 100–120 kD.
Their location on the vertical of BACE showed that both C
and MD contained disulfide-bonded BACE molecules (Fig.
5, a–f). In some of the gels (Fig. 5, a–c and f), the complexes
above the diagonal were clearly characterized by the presence
of two traces of radioactivity running parallel and very close
to each other. This showed that a second labeled protein was
disulfide bonded to BACE in the complexes. This protein
was PDI because complexes were decorated in immunoblots
by a monoclonal antibody to PDI (unpublished data), be-
cause the coordinates in the 2-D gels corresponded to those
of labeled PDI immunoprecipitated with specific antibody
Figure 5. Diagonal gel analysis of the 
association of PDI with BACE457 and 
BACE457 . Extract of cells expressing 
BACE457 or BACE457  were immuno-
precipitated with antiBACE (a, c, e, 
and g) or antiPDI (b, d, f, and h). After 
stringent washing to eliminate nonspecific 
interactions, samples were subjected 
to diagonal SDS-PAGE as described 
by Molinari and Helenius (1999). 
BACE in different oxidation states 
(shown with arrows) was the major 
labeled protein in the gels loaded with 
antiBACE precipitates. PDI was the 
major labeled protein in gels loaded 
with the antiPDI precipitates. Immuno-
precipitations were highly specific 
because abundant cytosolic (actin) or 
ER proteins (calreticulin and ERp72; 
unpublished data) did not coprecipitate 
with BACE or PDI. High molecular 
weight disulfide-bonded complexes 
are located above the diagonal of the gels and are shown with Cp (for their PDI component) and with Cb (for their BACE component). 
Mixed disulfides are shown with MDp and MDb, respectively. 
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from cell extracts (Fig. 5, AntiPDI), and because the com-
plexes containing disulfide-bonded BACE were also isolated
from cell extracts with PDI-specific antibody (Fig. 5, Anti-
PDI). We concluded that both C and MD disulfide-bonded
complexes had a BACE component (Cb and MDb) and a
PDI component (Cp and MDp) associated covalently via in-
terchain disulfide bonds. The complexes indicated with MD
were of particular interest because, according to their electro-
phoretic mobility, they consisted of a mixed disulfide be-
tween one PDI and one BACE molecule. Because mixed dis-
ulfides are formed between oxidoreductases and substrates
during catalysis of redox reactions (Huppa and Ploegh,
1998; Molinari and Helenius, 1999), the data supported the
involvement of PDI as an oxidoreductase during attempts of
BACE folding and during reduction of intra- and intermo-
lecular disulfide bonds to prepare misfolded BACE for dislo-
cation and degradation.
 
PDI is preferentially associated with oxidized BACE 
before the onset of degradation and with the reduced 
form of BACE during degradation
 
PDI was also noncovalently associated with BACE457 and
BACE457
 
 
 
, because a significant amount of monomeric
BACE in various oxidation states was visible on and below
the diagonal of gels loaded with the antiPDI precipitates.
After a 10-min chase, monomeric BACE457 was equally
distributed in the R, Ox1, and Ox2 states (Fig. 5 a). Of the
three oxidation states, Ox2 coprecipitated preferentially with
PDI (Fig. 5 b). Oxidation of BACE457
 
 
 
 was faster and after
a 10-min chase, 
 
 
 
70% of the labeled protein was fully oxi-
dized (Fig. 5 e, Ox2). All of the BACE457
 
 
 
 oxidation forms
present in the cells coprecipitated with PDI in amounts that
reflected their relative abundance in the cells. During the lag
phase, PDI (with BiP and calnexin; Fig. 4) was most likely in-
volved in the fruitless attempts to fold BACE and/or convert
BACE monomers into disulfide-bonded complexes.
During the degradation phase (after a 180-min chase for
BACE457 in Fig. 5 d and a 75-min chase for BACE457
 
 
 
 in
Fig. 5 h), PDI was preferentially associated with the reduced
form of BACE457 and BACE457
 
 
 
 (Fig. 5, d and i, R) and
only poorly with Ox2, though this was the more abundant
oxidation form present in the cells at this time of chase (Fig.
5, c and g, AntiBACE).
Overall, involvement of PDI in mixed disulfides with
BACE, and preferential association of the lumenal oxi-
doreductase with distinct oxidation forms of the ERAD can-
didates in different phases of the ERAD process, indicated a
dynamic and active role for PDI during the preparation of
BACE for dislocation into the cytosol. The fully reduced
form of BACE457 and BACE457
 
 
 
 associated with PDI in
the last moment of BACE permanence in the ER may repre-
sent dislocation-competent entities trapped in the act of be-
ing dislocated into the cytosol.
 
DTT inhibits dislocation and degradation of BACE
 
Reducing agents may accelerate protein degradation from
the ER (Stafford and Bonifacino, 1991; Young et al., 1993;
Courageot et al., 1999; Mancini et al., 2000; Wilson et al.,
2000), whereas oxidants may inhibit this process (Stafford
and Bonifacino, 1991; Mancini et al., 2000). These results
could be ascribed to a facilitated dislocation of reduced, un-
folded ERAD substrates.
To determine whether changes in the ER redox envi-
ronment also affected BACE degradation, cells were exposed
to low millimolar concentrations of diamide or DTT. As
expected, the oxidant diamide inhibited degradation of
BACE457 (unpublished data). Surprisingly, the reducing
agent DTT inhibited BACE degradation too (shown for
BACE457
 
 
 
 in Fig. 6 a where the effect of DTT is also com-
pared with other ERAD inhibitors). After a 75-min chase,
30% of BACE457
 
 
 
 was protected from degradation already in
the presence of 1 mM DTT (vs. 10% in control cells; Fig. 6 a).
At higher DTT concentrations (3 or 5 mM), protection from
degradation was comparable to that obtained with MG and
Kif (Fig. 6 a). At these concentrations of DTT, the intramolec-
ular disulfide bonds of BACE had been reduced because the
electrophoretic mobility of BACE457
 
  was the same under
nonreducing and reducing conditions (Fig. 6 a). BACE, theo-
retically in a fully unfolded state, was nevertheless not dislo-
cated into the cytosol, as determined by ultracentrifugation of
cell homogenates (unpublished data), and remained protected
from degradation (Fig. 6 a). Importantly, the DTT block was
reversible and BACE degradation from the ER was resumed,
with somewhat slower kinetics, upon DTT washout (Fig. 6 b).
Association of BACE with lumenal chaperones upon 
inhibition of the degradation process
To assess the mechanism by which BACE457 was retained
in the ER, inaccessible to the cytosolic ERAD machinery,
upon DTT treatment, we determined whether modification
of the ER redox environment resulted in the stable associa-
tion of the fully reduced protein with ER resident lumenal
Figure 6. Molecular chaperones involved in the retention of 
BACE upon inhibition of ERAD machinery. (a) Cells were mock 
treated or incubated for the times indicated with DJ, MG, Kif, or 
DTT at different concentrations. BACE457  was precipitated with 
specific antibody and analyzed by SDS-PAGE. (b) Cells were 
incubated for 90 min with 5 mM DTT. Upon DTT washout, the 
incubation was continued for the times indicated. (c) Cell extracts 
were precipitated with anticalnexin, antiBiP, or antiPDI, and then 
with antiBACE upon denaturation.254 The Journal of Cell Biology | Volume 158, Number 2, 2002
chaperones. Detergent extracts of cells mock treated or
treated with DTT, or with other ERAD inhibitors, were
subjected to immunoprecipitation with antibodies to cal-
nexin, BiP, or PDI as described above.
After a 90-min chase, BACE457  had been almost com-
pletely degraded and was therefore not found in association
with chaperones (Fig. 6 c, 90’). Analysis of the DTT-treated
cells revealed that after a 90-min chase, BACE was still asso-
ciated with PDI, to a lesser extent with BiP, but not with
calnexin (Fig. 6 c, DTT, AntiPDI, AntiBiP, and AntiCal-
nexin). These data showed that BACE dislocation and degra-
dation were inhibited in response to DTT treatment mainly
because DTT prevented BACE release from PDI. Upon
DTT washout, BACE was released from PDI and degrada-
tion was resumed as shown in Fig. 6 b.
Interestingly, PDI was only involved significantly in the re-
tention of BACE in the ER when the ERAD process was in-
hibited by DTT. The Ox1 form of BACE457  and disulfide-
bonded complexes were in fact mainly retained by BiP, when
degradation was prevented by MG (Fig. 6 c, AntiBiP, MG). It
remains to be established how Ox2 was retained in the ER
when degradation was inhibited by MG, because we only
found a small fraction of this oxidation form associated with a
chaperone, namely calnexin (Fig. 6 c, AntiCalnexin, MG).
The effect of Kif was to retard BACE457  release from
calnexin (Fig. 6 c, AntiCalnexin, Kif). A possible explanation
for this latter finding is that Man9 glycans are more effi-
ciently reglucosylated by the ER folding sensor glucosyl
transferase than Man8 sugars (Parodi, 2000). The persistence
of Man9 glycans in the presence of Kif would therefore favor
a prolonged retention of ERAD candidates in the calnexin
cycle. Association with calnexin was not sufficient, alone, to
explain the inhibitory effect of Kif on ERAD because upon
longer incubation, BACE457  was eventually released from
the chaperone, but protection from degradation persisted.
These data implied that Man9 glycans, per se, protect pro-
teins from degradation and/or that generation of Man8 is re-
quired to tag misfolded polypeptides for degradation.
We concluded that MG, Kif, and DTT treatments pre-
vented the dislocation of misfolded BACE into the cytosol,
confirming that degradation and dislocation are coupled
events. The retention mechanism was different for each one
of the inhibitors tested, involving the formation of disulfide-
bonded complexes and/or association with calnexin, BiP, or
PDI as the major retention mechanism.
Discussion
BACE457 is the splice variant of  -secretase found in the
pancreas. Compared with the brain isoform, BACE501,
BACE457 lacks 44 residues in the lumenal domain. Al-
though maturation of BACE501 transiently expressed in
HEK293 cells was efficient (this study; Sinha et al., 1999;
Vassar et al., 1999; Yan et al., 1999), we found that most of
the BACE457 expressed under similar conditions was re-
tained in the ER and became a substrate for ERAD.
The fate of BACE457 and of the soluble mutant
BACE457  was characterized by a lag phase during which
the proteins were extensively oxidized and remained pro-
tected from premature degradation during nonproductive
attempts at folding in association with the molecular chap-
erone calnexin. Upon release from calnexin, misfolded
BACE457 (and to a lesser extent BACE457 ) transiently en-
tered into disulfide-bonded complexes before degradation
from the ER. Because the lumenal portion of the two pro-
teins is identical, it is likely that attachment at the membrane,
or the transmembrane region itself, which contains two
cysteines, determined the longer association with calnexin,
the slower degradation, and the increased susceptibility to
aggregation observed for BACE457. Both BACE457 and
BACE457  remained trapped in disulfide-bonded com-
plexes when their degradation was inhibited, but their degra-
dation was resumed upon washout of the ERAD inhibitors.
This, and the transient formation of complexes during nor-
mal degradation of BACE457 implied disassembly of the
complexes and unfolding of BACE by reduction of intra- and
intermolecular disulfides to allow dislocation and protea-
some-mediated degradation. Dislocation of ERAD substrates
through the dislocon (Kopito, 1997) as well as access to the
proteasomal cavity (Rubin and Finley, 1995) require, in fact,
extensive unfolding of the polypeptide chain. Accumulation
of extensively oxidized species upon inhibition of the ERAD
machinery also implied that besides dislocation (Mayer et al.,
1998; Mancini et al., 2000), unfolding of ERAD candidates
before dislocation relies on active degradation machinery.
BACE457 or BACE457  were the major components of
the disulfide-bonded complexes. However, by coprecipita-
tion and diagonal gel analysis, we established that lumenal
chaperones, such as BiP and PDI (but not calnexin), were
also associated with the complexes. Based on the relatively
low molecular weight, we estimated that the disulfide-
bonded complexes contained up to 10 BACE457 or
BACE457  molecules in addition to fewer BiP and PDI
molecules. The number (and not the size) of these chaper-
one-containing complexes increased in the ER lumen when
degradation of misfolded BACE was inhibited, indicating
that they were units with limited capacity for accepting mis-
folded polypeptides.
Recent data showed that chaperone systems, such as BiP–
Jem1p–Scj1p, may prevent the formation of protein aggre-
gates in yeast (Fewell et al., 2001; Nishikawa et al., 2001).
In mammalian cells, at least for the substrates presented in
this study, association with BiP and PDI was not sufficient
to prevent the formation of disulfide-bonded complexes.
BiP and PDI might however play an important regulatory
role in keeping the size of the complexes under control,
thereby preventing their irreversible deposition. Protein ag-
gregation and deposition in intracellular compartments or
within tissues is in fact often an end point of protein mis-
folding associated with invalidating human pathologies
(conformational diseases; Kopito and Ron, 2000). The data
presented in this paper show that the formation of disulfide-
bonded complexes might be a reversible process in the mam-
malian ER, and that complexes may represent an intermedi-
ate state in which ERAD candidates are maintained as
degradation competent. Reversible aggregation of ERAD
candidates in the ER lumen may actually have a number of
advantages. First, it could represent a general mechanism to
effectively prevent transport of misfolded proteins along the
secretory pathway or their dislocation into the cytosol when Mechanisms of BACE457 ERAD | Molinari et al. 255
prompt degradation is not warranted. This is important for
cell viability, because it has recently been shown that aggre-
gation-prone polypeptides accumulating in the cytosolic
compartment damage the proteasome system and trigger cell
death (Bence et al., 2001). Second, it could facilitate the dis-
location process by concentrating misfolded products in spe-
cific regions of the ER lumen, possibly close to dislocons.
Concentration of misfolded products would also minimize
deleterious interference with the activity of the folding ma-
chinery or with nascent chains emerging in the ER lumen.
Third, the packaging of ERAD candidates would reduce the
number of lumenal chaperone molecules involved in the
regulation of protein degradation from the ER. This could
have important implications, because excessive sequestration
of lumenal chaperones by misfolded products triggers un-
folded protein responses and leads to impaired cell viability
(Urano et al., 2000). It was an important observation in this
contest that the reversible aggregation of misfolded
BACE457 during its ERAD did not trigger unfolded pro-
tein responses (as determined by lack of BiP up-regulation;
unpublished data).
Despite the significant difference in the rate of degrada-
tion for both BACE457 and BACE457 , the different ki-
netics of association with calnexin and with BiP/PDI clearly
supported a two-phase model in which the two-chaperone
systems acted sequentially during ERAD. Calnexin pro-
tected BACE457 and BACE457  from aggregation and
premature degradation, and assisted the newly synthesized
glycoproteins in fruitless attempts at folding. BiP and PDI
were also involved in this phase and then played an essential
role after the release of terminally misfolded BACE from cal-
nexin to prepare the covalently bonded and/or extensively
oxidized polypeptides for dislocation during ERAD, and to
maintain covalent complexes as degradation competent
when the ERAD machinery was inactive. Our data showed
therefore that the glycoprotein-specific calnexin cycle and
the BiP/PDI chaperone system may act in a coordinate fash-
ion not only to assist the maturation of newly synthesized
polypeptides as shown by Molinari and Helenius (2000),
but also to warrant the degradation of aberrant products that
are unable to reach a transport-competent conformation.
The mammalian ER contains at least half a dozen oxi-
doreductases that could be implicated in the reduction of in-
ter- and intramolecular disulfide bonds during the prepara-
tion of ERAD substrates for dislocation. Some of them are
implicated in the oxidative folding of newly synthesized pro-
teins in vivo (Molinari and Helenius, 1999), but none has
been found to be implicated in yeast or mammals in the en-
zymatic unfolding of polypeptides. An involvement of PDI
in the transport of proteins from the ER lumen into the cyto-
sol has been, on the other hand, recently proposed. Yeast
strains expressing PDI mutants were in fact defective in the
dislocation of misfolded proteins without cysteines (Gillece
et al., 1999). Moreover, experiments performed in vitro have
implicated PDI in the dislocation of the catalytic subunit of
cholera toxin during cellular intoxication (Tsai et al., 2001).
Here, we extend our knowledge of PDI functions in the ER.
Using a sensitive 2-D SDS-PAGE technique previously used
to determine the involvement of PDI and ERp57 in protein
folding (Molinari and Helenius, 1999), we established that
only PDI, of the oxidoreductases examined in this work, as-
sociated with BACE457 and BACE457  before their dislo-
cation into the cytosol. We identified mixed disulfides gener-
ated in the ER between PDI and BACE. This implied a
redox activity of PDI in the generation of intra- and intermo-
lecular disulfide bonds during and after the attempts-at-fold-
ing phase and/or in the reduction of disulfides to disentan-
gle BACE-containing complexes and unfold the misfolded
polypeptides to make them competent for dislocation.
The powerful 2-D technique used for our investigation also
allowed for detection of the noncovalent association of PDI
with fully reduced BACE, ready to be dislocated into the cyto-
sol. This putative intermediate of BACE dislocation was stabi-
lized, reversibly, upon modification of the ER redox environ-
ment. Reducing conditions generated in the ER by a low
millimolar concentration of DTT, in fact, blocked the release
of BACE from PDI, preventing both dislocation and degrada-
tion of the ERAD substrate. These data were somewhat sur-
prising because they contradict observations made for other
ERAD substrates; T cell receptor, major histocompatibility
complex class I, and immunoglobulin chains are degraded
faster under reducing conditions (Stafford and Bonifacino,
1991; Young et al., 1993; Courageot et al., 1999; Mancini et
al., 2000; Wilson et al., 2000). This could reflect differences
in the experimental models (semipermeabilized cells for T cell
receptor and major histocompatibility complex class I degra-
dation vs. living cells for our studies) and/or different mecha-
nisms of preparation for degradation used by different pro-
teins. Importantly, degradation of BACE was resumed when
physiological redox conditions were reestablished upon DTT
removal. These data hint at a redox-driven chaperone activity
of PDI during ERAD of BACE, similar to that reported for
PDI during dislocation of the A chain of cholera toxin into
the cytosol (Tsai et al., 2001). Binding and release of ERAD
substrates would be regulated by a redox cycle in which the re-
duced form of PDI would associate with substrates and sub-
strate release would require reoxidation of PDI.
Materials and methods
Mammalian expression constructs and antibodies
Plasmids for expression of BACE457 and BACE501, and antibody to BACE
are described by Bodendorf et al. (2001). Antibodies to PDI, calnexin, and
ERp29 were gifts from Ineke Braakman (Utrecht University, Utrecht, Neth-
erlands), Ari Helenius (ETH, Zurch, Switzerland), and Souren Mkrtchian
(Karolinski Institute, Stockholm, Sweden). Antibody to ERp57 is described
by Molinari and Helenius (1999). Antibodies to BiP, ERp72, calreticulin,
and actin are commercially available (StressGen Biotechnologies).
Cell culture and transfection
HEK293 cells were grown in DME, 10% FBS, penicillin, streptomycin
(GIBCO BRL). Cells were plated in 6-cm Petri dishes to 90% confluency
and transfected with 3–6  g plasmid DNA and 20  l Lipofectamine2000
(GIBCO BRL) per dish. Transient expression was allowed for 15–24 h.
Metabolic labeling, preparation of cell extracts, 
immunoprecipitation, endoglycosidase treatment, 
diagonal electrophoresis, and sucrose gradients
Cells were starved for 30 min in Met/Cys-free medium, pulsed for 10 min
with 150  Ci [
35S]Met/Cys in 1 ml starvation medium/dish and chased for
the times indicated in the figures with DME supplemented with 5 mM cold
Met/Cys. At the end of a chase, cells were flooded with 20 mM ice-cold
N-ethylmaleimide to prevent postlysis oxidation of free cysteines. Postnu-
clear supernatants were prepared by solubilization of cells in 800  l/dish
of ice-cold 2% CHAPS-Hepes buffer saline, pH 6.8, containing N-ethylma-256 The Journal of Cell Biology | Volume 158, Number 2, 2002
leimide, protease inhibitors (HBS), and 20 U apyrase (Sigma-Aldrich) per
dish when associations with BiP were investigated. Release of substrates
from BiP requires ADP–ATP exchange. By rapidly depleting ATP from cell
extracts, apyrase stabilizes BiP–substrate complexes before immunopre-
cipitation. Cell extracts were prepared by a 10-min centrifugation at
10,000 g and analyzed after immunoprecipitation with specific antibodies
by nonreducing, reducing, or diagonal SDS-PAGE. Relevant bands were
quantitated by ImageQuant software (Molecular Dynamics). At least three
independent experiments were analyzed. All kinetics shown in the paper
represent an average of the experiments considered. For EndoH (Roche
Molecular Biochemicals) treatment, immunoprecipitated BACE457 or
BACE501 were incubated for 1 h at 37 C with 5 mU of EndoH. Samples
were then analyzed by reducing SDS-PAGE. For diagonal electrophoresis,
the precipitates were first subjected to nonreducing SDS-PAGE in capillary
tubes. The gels were extruded from the tubes, boiled for 10 min in reduc-
ing sample buffer, placed onto conventional slab gels, and subjected to a
second electrophoresis under reducing conditions (this technique is de-
scribed in detail in Molinari and Helenius, 2002). Immunoprecipitations
were performed by adding protein A beads (PAB, 1:10 wt/vol swollen in
HBS; Sigma-Aldrich) and the selected antibody to the cell extracts. Incuba-
tions were for 1–4 h in a cold room. The immunoprecipitates were exten-
sively washed, three times, with HBS and 0.5% CHAPS and resuspended
in sample buffer for SDS-PAGE. When association with lumenal chaper-
ones was examined, after the first immunoprecipitation with chaperone-
specific antibody, the beads were washed three times, boiled in 100  l 1%
SDS in HBS to denature the precipitate, and supplemented with 1 ml Tri-
ton X-100 (1% in HBS), fresh protein A beads, and antibody to a linear
epitope of BACE to perform the second immunoprecipitation. After three
extensive washes, beads were resuspended in sample buffer and subjected
to SDS-PAGE. To determine the size of disulfide-bonded BACE457, 100  l
of detergent extracts were overlaid on a 10–25%, linear sucrose gradient
prepared with a gradient master (Biocomp) and centrifuged for 3 h at
260,000 g (rotor MLS50; Beckman Coulter).
Inhibitors
L (20  M; Calbiochem), MG (20  M; Calbiochem), or Kif (1–10  g/ml;
Toronto Research Chemicals) was added 30 min before the pulse and was
maintained during the pulse and throughout the chase unless specified. N
was used at 5 mM and MA at 10 mM. The glucosidase inhibitor DJ (1 mM)
was added to the cells after a 10-min chase and was maintained until the
end of the chase to inhibit substrate release from calnexin. It was added
during starvation, pulse, and chase to prevent substrate association with
calnexin as described by Hammond et al. (1994).
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